Elizei Sanam Salimi, Kwon Brian K
International Collaboration on Repair Discoveries (ICORD), University of British Columbia, BC, Canada.
Vancouver Spine Surgery Institute, Department of Orthopaedics, University of British Columbia, BC, Canada.
Neural Regen Res. 2017 Mar;12(3):385-388. doi: 10.4103/1673-5374.202933.
The evaluation of such novel therapies for acute spinal cord injury in clinical trials is extremely challenging. Our current dependence upon the clinical assessment of neurologic impairment renders many acute SCI patients ineligible for trials because they are not examinable. Furthermore, the difficulty in predicting neurologic recovery based on the early clinical assessment forces investigators to recruit large cohorts to have sufficient power. Biomarkers that objectively classify injury severity and better predict neurologic outcome would be valuable tools for translational research. As such, the objective of the present review was to describe some of the translational challenges in acute spinal cord injury research and examine the potential utility of neurochemical biomarkers found within cerebrospinal fluid and blood. We focus on published efforts to establish biological markers for accurately classifying injury severity and precisely predict neurological outcome.
在临床试验中评估此类针对急性脊髓损伤的新型疗法极具挑战性。我们目前依赖于对神经功能缺损的临床评估，这使得许多急性脊髓损伤患者因无法接受检查而不符合试验条件。此外，基于早期临床评估来预测神经功能恢复的困难迫使研究人员招募大量队列以获得足够的效力。能够客观地对损伤严重程度进行分类并更好地预测神经功能结果的生物标志物将是转化研究的宝贵工具。因此，本综述的目的是描述急性脊髓损伤研究中的一些转化挑战，并探讨脑脊液和血液中发现的神经化学生物标志物的潜在效用。我们重点关注已发表的关于建立生物标志物以准确分类损伤严重程度并精确预测神经功能结果的研究。
